Abstract
Tumor-associated gangliosides play important roles in regulation of signal transduction induced by growth-factor receptors including EGFR, FGFR, HGF and PDGFR in a specific microdomain called glycosynapse in the cancer cell membranes, and in interaction with glycan recognition molecules involved in cell adhesion and immune regulation including selectins and siglecs. As the genes involved in the synthesis and degradation of tumor-associated gangliosides were identified, biological functions became clearer from the experimental results employing forced overexpression and/or knockdown/knockout of the genes. Studies on the regulatory mechanisms for their expression also achieved great advancements. Epigenetic silencing of glycan-related genes is a dominant mechanism in glycan alteration at early stages of carcinogenesis. Development of hypoxia resistance involving activation of a transcription factor HIF, and acquisition of cancer stem cell-like characteristics through epithelial–mesenchymal transition are important mechanisms for glycan modulations in the later stages of cancer progression. In the initial stages of studies, the gangliosides which specifically appear in cancers attracted attention under the name of tumor-associated gangliosides. However, it became apparent that not only the cancer-associated gangliosides but also the normal gangliosides present in nonmalignant cells and tissues perform important biological functions, and some of them tend to disappear in cancer cells resulting in the loss of the physiological functions, and this sometimes facilitates progression of cancers.
Keywords
- Cancer stem cells
- De novo synthesis
- DNA hypermethylation
- Embryonic stem cells
- Epigenetic silencing
- Epithelial–mesenchymal transition (EMT)
- Glycolipid enriched microdomain (GEM)
- Glycosynapse
- Hematogenous metastasis
- Histone modification
- Hypoxia inducible factor (HIF)
- Incomplete synthesis
- MicroRNA
- Scavenger pathway
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- EMT:
-
Epithelial–mesenchymal transition
- GEM:
-
Glycolipid enriched microdomain
- HIF:
-
Hypoxia inducible factor
- iPS cells:
-
Inducible pluripotent stem cells
- SSEA:
-
Stage-specific embryonic antigen
References
No authors listed (2015) Dinutuximab approved for high-risk neuroblastoma. Cancer Discov 5:OF5
Dhillon S (2015) Dinutuximab: first global approval. Drugs 75:923–927
Gabri MR, Cacciavillano W, Chantada GL, Alonso DF (2016) Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert Opin Biol Ther 16:573–578
Hakomori SI, Murakami WT (1968) Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc Natl Acad Sci U S A 59:254–261
Hakomori SI (2010) Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett 584:1901–1906
Hakomori SI, Handa K (2015) GM3 and cancer. Glycoconj J 32:1–8
Zhou Q, Hakomori S, Kitamura K, Igarashi Y (1994) GM3 directly inhibits tyrosine phosphorylation and De-N-acetyl-GM3 directly enhances serine phosphorylation of epidermal growth factor receptor, independently of receptor-receptor interaction. J Biol Chem 269:1959–1965
Liu JW, Sun P, Yan Q, Paller AS, Gerami P, Ho N et al (2009) De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res 69:8662–8669
Kawashima N, Qu H, Lobaton M, Zhu Z, Sollogoub M, Cavenee WK et al (2014) Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. Oncol Lett 7:933–940
Noguchi M, Suzuki T, Kabayama K, Takahashi H, Chiba H, Shiratori M et al (2007) GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Sci 98:1625–1632
Kawashima N, Nishimiya Y, Takahata S, Nakayama KI (2016) Induction of glycosphingolipid GM3 expression by valproic acid suppresses cancer cell growth. J Biol Chem 291:21424–21433
Prinetti A, Aureli M, Illuzzi G, Prioni S, Nocco V, Scandroglio F et al (2010) GM3 synthase overexpression results in reduced cell motility and in caveolin-1 upregulation in human ovarian carcinoma cells. Glycobiology 20:62–77
Prinetti A, Prioni S, Loberto N, Aureli M, Nocco V, Illuzzi G et al (2011) Aberrant glycosphingolipid expression and membrane organization in tumor cells: consequences on tumor-host interactions. Adv Exp Med Biol 705:643–667
Prinetti A, Cao T, Illuzzi G, Prioni S, Aureli M, Gagliano N et al (2011) A glycosphingolipid/caveolin-1 signaling complex inhibits motility of human ovarian carcinoma cells. J Biol Chem 286:40900–40910
Roncati L, Barbolini G, Gatti AM, Pusiol T, Piscioli F, Maiorana A (2016) The uncontrolled sialylation is related to chemoresistant metastatic breast cancer. Pathol Oncol Res 22:869–873
Choi SY, Jang JH, Kim KR (2011) Analysis of differentially expressed genes in human rectal carcinoma using suppression subtractive hybridization. Clin Exp Med 11:219–226
Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K, Hakomori SI (2013) Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A 110:4968–4973
Mathow D, Chessa F, Rabionet M, Kaden S, Jennemann R, Sandhoff R et al (2015) Zeb1 affects epithelial cell adhesion by diverting glycosphingolipid metabolism. EMBO Rep 16:321–331
Kilbey A, Terry A, Jenkins A, Borland G, Zhang Q, Wakelam MJ et al (2010) Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res 70:5860–5869
Cai H, Zhou H, Miao Y, Li N, Zhao L, Jia L (2017) MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5. Lab Investig 97(5):530–542
Shiozaki K, Takahashi K, Hosono M, Yamaguchi K, Hata K, Shiozaki M et al (2015) Phosphatidic acid-mediated activation and translocation to the cell surface of sialidase NEU3, promoting signaling for cell migration. FASEB J 29:2099–2111
Kakugawa Y, Wada T, Yamaguchi K, Yamanami H, Ouchi K, Sato I et al (2002) Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci U S A 99:10718–10723
Miyagi T, Takahashi K, Hata K, Shiozaki K, Yamaguchi K (2012) Sialidase significance for cancer progression. Glycoconj J 29:567–577
Wada T, Hata K, Yamaguchi K, Shiozaki K, Koseki K, Moriya S et al (2007) A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells. Oncogene 26:2483–2490
Mozzi A, Forcella M, Riva A, Difrancesco C, Molinari F, Martin V et al (2015) NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels. Glycobiology 25:855–868
Yamaguchi K, Shiozaki K, Moriya S, Koseki K, Wada T, Tateno H et al (2012) Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase. PLoS One 7:e41132
Yamaguchi K, Koseki K, Shiozaki M, Shimada Y, Wada T, Miyagi T (2010) Regulation of plasma-membrane-associated sialidase NEU3 gene by Sp1/Sp3 transcription factors. Biochem J 430:107–117
Scaringi R, Piccoli M, Papini N, Cirillo F, Conforti E, Bergante S et al (2013) NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from apoptosis through the activation of the epidermal growth factor receptor signaling pathway and the hypoxia-inducible factor (HIF)-1α. J Biol Chem 288:3153–3162
Yuyama Y, Dohi T, Morita H, Furukawa K, Oshima M (1995) Enhanced expression of GM2/GD2 synthase mRNA in human gastrointestinal cancer. Cancer 75:1273–1280
Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G et al (2006) GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 66:6816–6825
Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M et al (2009) Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol 183:5050–5058
Kundu M, Mahata B, Banerjee A, Chakraborty S, Debnath S, Ray SS et al (2016) Ganglioside GM2 mediates migration of tumor cells by interacting with integrin and modulating the downstream signaling pathway. Biochim Biophys Acta 1863:1472–1489
Mahata B, Banerjee A, Kundu M, Bandyopadhyay U, Biswas K (2015) TALEN mediated targeted editing of GM2/GD2-synthase gene modulates anchorage independent growth by reducing anoikis resistance in mouse tumor cells. Sci Rep 5:9048
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI (2008) Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci U S A 105:1925–1930
Dall’Olio F, Malagolini N, Chiricolo M, Trinchera M, Harduin-Lepers A (2014) The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2. Biochim Biophys Acta 1840:443–453
Tanaka K, Miyazawa M, Mikami M, Aoki D, Kiguchi K, Iwamori M (2016) Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines. Glycoconj J 33:745–754
Kawamura YI, Toyota M, Kawashima R, Hagiwara T, Suzuki H, Imai K et al (2008) DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 135:142–151
Malagolini N, Santini D, Chiricolo M, Dall'Olio F (2007) Biosynthesis and expression of the Sda and sialyl Lewis x antigens in normal and cancer colon. Glycobiology 17:688–697
Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W et al (2011) Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci 102:2157–2163
Li Q, Wang W, Machino Y, Yamada T, Kita K, Oshima M et al (2015) Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. Cancer Sci 106:102–107
Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P et al (2013) Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31:3831–3837
Furukawa K, Hamamura K, Ohkawa Y, Ohmi Y (2012) Disialyl gangliosides enhance tumor phenotypes with differential modalities. Glycoconj J 29:579–584
Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO et al (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122:2066–2078
Yeh SC, Wang PY, Lou YW, Khoo KH, Hsiao M, Hsu TL et al (2016) Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity. Proc Natl Acad Sci U S A 113:5592–5597
Ruckhaberle E, Karn T, Rody A, Hanker L, Gatje R, Metzler D et al (2009) Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol 135:1005–1013
Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A et al (2010) GD synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 8:1526–1535
Furukawa K, Kambe M, Miyata M, Ohkawa Y, Tajima O (2014) Ganglioside GD3 induces convergence and synergism of adhesion and hepatocyte growth factor/Met signals in melanomas. Cancer Sci 105:52–63
Bobowski M, Vincent A, Steenackers A, Colomb F, Van S, Julien S et al (2013) Estradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFκB binding to ST8SIA1 promoter. PLoS One 8:e62559
Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Pena EQ, Taube JH et al (2015) GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 34:2958–2967
Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NF et al (2014) A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer 14:54–14
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324–1334
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009
Lorusso G, Ruegg C (2012) New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 22:226–233
Hu G, Kang Y, Wang XF (2009) From breast to the brain: unraveling the puzzle of metastasis organotropism. J Mol Cell Biol 1:3–5
Vandermeersch S, Vanbeselaere J, Delannoy CP, Drolez A, Mysiorek C, Guerardel Y et al (2015) Accumulation of GD1α ganglioside in MDA-MB-231 breast cancer cells expressing ST6GalNAc V. Molecules 20:6913–6924
Drolez A, Vandenhaute E, Delannoy CP, Dewald JH, Gosselet F, Cecchelli R et al (2016) ST6GALNAC5 expression decreases the interactions between breast cancer cells and the human blood-brain barrier. Int J Mol Sci 17:E1309
Bhuiyan RH, Kondo Y, Yamaguchi T, Tokuda N, Ohkawa Y, Hashimoto N et al (2016) Expression analysis of 0-series gangliosides in human cancer cell lines with monoclonal antibodies generated using knockout mice of ganglioside synthase genes. Glycobiology 26:984–998
Kroes RA, Dawson G, Moskal JR (2007) Focused microarray analysis of glyco-gene expression in human glioblastomas. J Neurochem 103(Suppl 1):14–24
Kroes RA, He H, Emmett MR, Nilsson CL, Leach FE III, Amster IJ et al (2010) Overexpression of ST6GalNAcV, a ganglioside-specific α2,6-sialyltransferase, inhibits glioma growth in vivo. Proc Natl Acad Sci U S A 107:12646–12651
Samraj AN, Laubli H, Varki N, Varki A (2014) Involvement of a non-human sialic acid in human cancer. Front Oncol 4:33
Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen G-Y, Takematsu H et al (2006) Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 66:2937–2945
Go S, Sato C, Yin J, Kannagi R, Kitajima K (2007) Hypoxia-enhanced expression of free deaminoneuraminic acid in human cancer cells. Biochem Biophys Res Commun 357:537–542
Laughlin ST, Bertozzi CR (2007) Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation. Nat Protoc 2:2930–2944
Bull C, Boltje TJ, Wassink M, de Graaf AM, van Delft FL, den Brok MH et al (2013) Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol Cancer Ther 12:1935–1946
Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M et al (2013) Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 104:43–47
Inoue S, Sato C, Kitajima K (2010) Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. Glycobiology 20:752–762
Nystedt J, Anderson H, Hirvonen T, Impola U, Jaatinen T, Heiskanen A et al (2010) Human CMP-N-acetylneuraminic acid hydroxylase is a novel stem cell marker linked to stem cell-specific mechanisms. Stem Cells 28:258–267
Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O et al (1996) Gangliosides expressed in human breast cancer. Cancer Res 56:5165–5171
Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C et al (2000) A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19:241–247
Blanco R, Rengifo E, Cedeno M, Rengifo CE, Alonso DF, Carr A (2011) Immunoreactivity of the 14F7 Mab raised against N-glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol 2011:645641
Blanco R, Dominguez E, Morales O, Blanco D, Martinez D, Rengifo CE et al (2015) Prognostic significance of N-glycolyl GM3 ganglioside expression in non-small cell lung carcinoma patients: new evidences. Pathol Res Int 2015:132326
Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C et al (2011) Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011:245181
Miyake M, Ito M, Hitomi S, Ikeda S, Taki T, Kurata M et al (1988) Generation of two monoclonal antibodies that can discriminate N-glycolyl and N-acetyl neuraminic acid residues of GM2 gangliosides and distribution of the antigens in human lung cancer. Cancer Res 48:6154–6160
Kawashima I, Ozawa H, Kotani M, Suzuki M, Kawano T, Gomibuchi M et al (1993) Characterization of ganglioside expression in human melanoma cells: immunological and biochemical analysis. J Biochem (Tokyo) 114:186–193
Palomo AG, Santana RB, Perez XE, Santana DB, Gabri MR, Monzon KL et al (2016) Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications. Clin Exp Metastasis 33:717–725
Herrera ZM, Ramos TC (2014) Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 63:737–747
Alfonso S, Valdes-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernandez M et al (2014) A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 20:3660–3671
Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R et al (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168:2523–2529
Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M et al (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107:80–89
Hernandez AM, Rodriguez M, Lopez-Requena A, Beausoleil I, Perez R, Vazquez AM (2005) Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: a self versus non-self-matter. Immunobiology 210:11–21
Solter D, Knowles BB (1978) Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc Natl Acad Sci U S A 75:5565–5569
Handa K, Hakomori SI (2016) Changes of glycoconjugate expression profiles during early development. Glycoconj J 34(6):693–699
Kannagi R, Cochran NA, Ishigami F, Hakomori S, Andrews PW, Knowles BB et al (1983) Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J 2:2355–2361
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:1–12
Yu AL, Hung JT, Ho MY, Yu J (2016) Alterations of glycosphingolipids in embryonic stem cell differentiation and development of glycan-targeting cancer immunotherapy. Stem Cells Dev 25:1532–1548
Saito S, Orikasa S, Satoh M, Ohyama C, Ito A, Takahashi T (1997) Expression of globo-series gangliosides in human renal cell carcinoma. Jpn J Cancer Res 88:652–659
Tokuyama S, Saito S, Takahashi T, Ohyama C, Ito A, Kanto S et al (2003) Immunostaining of stage-specific embryonic antigen-4 in intratubular germ cell neoplasia unclassified and in testicular germ-cell tumors. Oncol Rep 10:1097–1104
Huang YL, Hung JT, Cheung SK, Lee HY, Chu KC, Li ST et al (2013) Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc Natl Acad Sci U S A 110:2517–2522
Gottschling S, Jensen K, Warth A, Herth FJ, Thomas M, Schnabel PA et al (2013) Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis. Eur Respir J 41:656–663
Malecki M, Anderson M, Beauchaine M, Seo S, Tambokan X (2012) TRA-1-60(+), SSEA-4(+), Oct4A(+), Nanog(+) clones of pluripotent stem cells in the embryonal carcinomas of the ovaries. J Stem Cell Res Ther 2:130
Zhang W, Ding ML, Zhang JN, Qiu JR, Shen YH, Ding XY et al (2015) mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma. Sci Rep 5:9604. https://doi.org/10.1038/:9604
Noto Z, Yoshida T, Okabe M, Koike C, Fathy M, Tsuno H et al (2013) CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics. Oral Oncol 49:787–795
Lou YW, Wang PY, Yeh SC, Chuang PK, Li ST, Wu CY et al (2014) Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proc Natl Acad Sci U S A 111:2482–2487
Wenk J, Andrews PW, Casper J, Hata J, Pera MF, von Keitz A et al (1994) Glycolipids of germ cell tumors: extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells. Int J Cancer 58:108–115
Aloia A, Petrova E, Tomiuk S, Bissels U, Deas O, Saini M et al (2015) The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features. Breast Cancer Res 17:146–652
Sivasubramaniyan K, Harichandan A, Schilbach K, Mack AF, Bedke J, Stenzl A et al (2015) Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. Glycobiology 25:902–917
Malecki M, Tombokan X, Anderson M, Malecki R, Beauchaine M (2013) TRA-1-60+, SSEA-4+, POU5F1+, SOX2+, NANOG+ Clones of pluripotent stem cells in the embryonal carcinomas of the testes. J Stem Cell Res Ther 3:1000134
Virant-Klun I, Kenda-Suster N, Smrkolj S (2016) Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer. J Ovarian Res 9:12–221
Cheng J, Yang K, Zhang Q, Yu Y, Meng Q, Mo N et al (2016) The role of mesenchymal stem cells in promoting the transformation of androgen-dependent human prostate cancer cells into androgen-independent manner. Sci Rep 6:16993
Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R et al (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006–1020
Ye F, Li Y, Hu Y, Zhou C, Chen H (2010) Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma. Int J Gynecol Cancer 20:958–964
Cheung SK, Chuang PK, Huang HW, Hwang-Verslues WW, Cho CH, Yang WB et al (2016) Stage-specific embryonic antigen-3 (SSEA-3) and β3GalT5 are cancer specific and significant markers for breast cancer stem cells. Proc Natl Acad Sci U S A 113:960–965
Saito S, Aoki H, Ito A, Ueno S, Wada T, Mitsuzuka K et al (2003) Human α2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase. J Biol Chem 278:26474–26479
Izzi B, Binder AM, Michels KB (2014) Pyrosequencing evaluation of widely available bisulfite conversion methods: considerations for application. Med Epigenet 2:28–36
Magalhaes A, Marcos-Pinto R, Nairn AV, dela RM, Ferreira RM, Junqueira-Neto S et al (2015) Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. Biochim Biophys Acta 1852:1928–1939
Dunn CA, Medstrand P, Mager DL (2003) An endogenous retroviral long terminal repeat is the dominant promoter for human β1,3-galactosyltransferase 5 in the colon. Proc Natl Acad Sci U S A 100:12841–12846
Dunn CA, van de Lagemaat LN, Baillie GJ, Mager DL (2005) Endogenous retrovirus long terminal repeats as ready-to-use mobile promoters: the case of primate β3GAL-T5. Gene 364:2–12
Trinchera M, Zulueta A, Caretti A, Dall'Olio F (2014) Control of glycosylation-related genes by DNA methylation: the intriguing case of the B3GALT5 gene and its distinct promoters. Biology (Basel) 3:484–497
Zulueta A, Caretti A, Signorelli P, Dall'Olio F, Trinchera M (2014) Transcriptional control of the B3GALT5 gene by a retroviral promoter and methylation of distant regulatory elements. FASEB J 28:946–955
Steelant WF, Kawakami Y, Ito A, Handa K, Bruyneel EA, Mareel M et al (2002) Monosialyl-Gb5 organized with cSrc and FAK in GEM of human breast carcinoma MCF-7 cells defines their invasive properties. FEBS Lett 531:93–98
Hung TC, Lin CW, Hsu TL, Wu CY, Wong CH (2013) Investigation of SSEA-4 binding protein in breast cancer cells. J Am Chem Soc 135:5934–5937
Levery SB, Salyan MEK, Steele SJ, Kannagi R, Dasgupta S, Chien JL et al (1994) A revised structure for the disialosyl globo-series gangliosides of human erythrocytes and chicken skeletal muscle. Arch Biochem Biophys 312:125–134
Kawasaki Y, Ito A, Kakoi N, Shimada S, Itoh J, Mitsuzuka K et al (2015) Ganglioside, disialosyl globopentaosylceramide (DSGb5), enhances the migration of renal cell carcinoma cells. Tohoku J Exp Med 236:1–7
Shimada S, Ito A, Kawasaki Y, Kakoi N, Taima T, Mitsuzuka K et al (2014) Ganglioside disialosyl globopentaosylceramide is an independent predictor of PSA recurrence-free survival following radical prostatectomy. Prostate Cancer Prostatic Dis 17:199–205
Senda M, Ito A, Tsuchida A, Hagiwara T, Kaneda T, Nakamura Y et al (2007) Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers. Biochem J 402:459–470
Kannagi R, Levery SB, Hakomori S (1984) Blood group H antigen with globo-series structure: Isolation and characterization from human blood group O erythrocytes. FEBS Lett 175:397–401
Bremer EG, Levery SB, Sonnio S, Ghidoni R, Canevari S, Kannagi R et al (1984) Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neo-plastic epithelial cells of human mammary gland. J Biol Chem 259:14773–14777
Chang WW, Lee CH, Lee P, Lin J, Hsu CW, Hung JT et al (2008) Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci U S A 105:11667–11672
Cheng JY, Wang SH, Lin J, Tsai YC, Yu J, Wu JC et al (2014) Globo-H ceramide shed from cancer cells triggers translin-associated factor X-dependent angiogenesis. Cancer Res 74:6856–6866
Clausen H, Watanabe K, Kannagi R, Levery SB, Nudelman E, Arao-Tomono Y et al (1984) Blood group A glycolipid (Ax) with globo-series structure which is specific for blood group A1 erythrocytes: one of the chemical bases for A1 and A2 distinction. Biochem Biophys Res Commun 124:523–529
Sekine M, Taya C, Kikkawa Y, Yonekawa H, Takenaka M, Matsuoka Y et al (2001) Regulation of mouse kidney tubular epithelial cell-specific expression of core 2 GlcNAc transferase. Eur J Biochem 268:1129–1135
Suzuki A, Yoshioka S, Sekine M, Yonekawa H, Takenaka M, Kannagi R (2004) Core 2 GlcNAc transferase and kidney tubular cell-specific expression. Glycoconj J 20:151–156
Lowe JB, Stoolman LM, Nair RP, Larsen RD, Berhend TL, Marks RM (1990) ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA. Cell 63:475–484
Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S et al (1990) ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 250:1130–1132
Walz G, Aruffo A, Kolanus W, Bevilacqua M, Seed B (1990) Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science 250:1132–1135
Kannagi R (1997) Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J 14:577–584
Tei K, Kawakami-Kimura N, Taguchi O, Kumamoto K, Higashiyama S, Taniguchi N et al (2002) Roles of cell adhesion molecules in tumor angiogenesis induced by co-transplantation of cancer and endothelial cells to nude rats. Cancer Res 62:6289–6296
Cui HX, Wang H, Wang Y, Song J, Tian H, Xia C et al (2016) ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules. Oncol Rep 36:3317–3324
Higai K, Miyazaki N, Azuma Y, Matsumoto K (2006) Interleukin-1β induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene. FEBS Lett 580:6069–6075
Yoshihama N, Yamaguchi K, Chigita S, Mine M, Abe M, Ishii K et al (2015) A novel function of CD82/KAI1 in sialyl Lewis antigen-mediated adhesion of cancer cells: Evidence for an anti-metastasis effect by down-regulation of sialyl Lewis antigens. PLoS One 10:e0124743
Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D et al (2011) Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res 71:7683–7693
Martin-Satue M, de Castellarnau C, Blanco J (1999) Overexpression of α(1,3)-fucosyltransferase VII is sufficient for the acquisition of lung colonization phenotype in human lung adenocarcinoma HAL-24Luc cells. Br J Cancer 80:1169–1174
Carvalho AS, Harduin-Lepers A, Magalhaes A, Machado E, Mendes N, Costa LT et al (2010) Differential expression of α-2,3-sialyltransferases and α-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells. Int J Biochem Cell Biol 42:80–89
Shiozaki K, Yamaguchi K, Takahashi K, Moriya S, Miyagi T (2011) Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4. J Biol Chem 286:21052–21061
Vecchio G, Parascandolo A, Allocca C, Ugolini C, Basolo F, Moracci M et al (2017) Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer. Oncotarget 8(16):27075–27092
Cheng TC, Tu SH, Chen LC, Chen MY, Chen WY, Lin YK et al (2015) Down-regulation of α-L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface. Oncotarget 6:21283–21300
Ezawa I, Sawai Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H et al (2016) Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Sci 107:734–745
Baudot AD, Crighton D, O'Prey J, Somers J, Sierra GP, Ryan KM (2016) p53 directly regulates the glycosidase FUCA1 to promote chemotherapy-induced cell death. Cell Cycle 15:2299–2308
Kannagi R (2004) Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression – the Warburg effect revisited. Glycoconj J 20:353–364
Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S et al (2004) Hypoxia induces adhesion molecules on cancer cells—a missing link between Warburg effect and induction of selectin ligand carbohydrates. Proc Natl Acad Sci U S A 101:8132–8137
Mitsuoka C, Sawada-Kasugai M, Ando-Furui K, Izawa M, Nakanishi H, Nakamura S et al (1998) Identification of a major carbohydrate capping group of the L-selectin ligand on high endothelial venules in human lymph nodes as 6-sulfo sialyl Lewis x. J Biol Chem 273:11225–11233
Izawa M, Kumamoto K, Mitsuoka C, Kanamori A, Ohmori K, Ishida H et al (2000) Expression of sialyl 6-sulfo Lewis x is inversely correlated with conventional sialyl Lewis x expression in human colorectal cancer. Cancer Res 60:1410–1416
Yusa A, Miyazaki K, Kimura N, Izawa M, Kannagi R (2010) Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells. Cancer Res 70:4064–4073
Hakomori S, Kannagi R (1983) Glycosphingolipids as tumor-associated and differentiation markers. J Natl Cancer Inst 71:231–251
Kannagi R, Yin J, Miyazaki K, Izawa M (2008) Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori’s concepts revisited. Biochim Biophys Acta 1780:525–531
Kannagi R, Sakuma K, Miyazaki K, Lim K-T, Yusa A, Yin J et al (2010) Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers. Cancer Sci 101:586–593
Miyazaki K, Sakuma K, Kawamura YI, Izawa M, Ohmori K, Mitsuki M et al (2012) Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors, siglec-7 and -9. J Immunol 188:4690–4700
Varki A, Angata T (2006) Siglecs—the major subfamily of I-type lectins. Glycobiology 16:1R–27R
Zhang L, Shi J, Ji M, Liu W, Wang N, Guan H et al (2012) Methylation analysis of drug metabolism and transport genes in papillary thyroid cancer. Adv Sci Lett 17:243–250
Inoue A, Okamoto K, Fujino Y, Nakagawa T, Muguruma N, Sannomiya K et al (2015) B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P. Br J Cancer 112:403–412
Kimura N, Mitsuoka C, Kanamori A, Hiraiwa N, Uchimura K, Muramatsu T et al (1999) Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by co-transfection of α1→3 fucosyltransferase VII and newly cloned GlcNAcβ: 6-sulfotransferase cDNA. Proc Natl Acad Sci U S A 96:4530–4535
Shida K, Misonou Y, Korekane H, Seki Y, Noura S, Ohue M et al (2009) Unusual accumulation of sulfated glycosphingolipids in colon cancer cells. Glycobiology 19:1018–1033
Sakuma K, Aoki M, Kannagi R (2012) Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 109:7776–7781
Kannagi R (2007) Carbohydrate antigen sialyl Lewis a -its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 30:189–209
Magnani JL, Brockhaus M, Smith DF, Ginsburg V, Blaszczyk M, Mitchell KF et al (1981) A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science 212:55–56
Takada A, Ohmori K, Takahashi N, Tsuyuoka K, Yago K, Zenita K et al (1991) Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochem Biophys Res Commun 179:713–719
Berg EL, Robinson MK, Mansson O, Butcher EC, Magnani JL (1991) A carbohydrate domain common to both sialyl Lea and sialyl Lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem 266:14869–14872
Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M et al (1993) Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53:354–361
Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N (2004) Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95:377–384
Chung TW, Kim SJ, Choi HJ, Song KH, Jin UH, Yu DY et al (2014) Hepatitis B virus X protein specially regulates the sialyl lewis a synthesis among glycosylation events for metastasis. Mol Cancer 13:222
Hu H, Eggers K, Chen W, Garshasbi M, Motazacker MM, Wrogemann K et al (2011) ST3GAL3 mutations impair the development of higher cognitive functions. Am J Hum Genet 89:407–414
Grahn A, Barkhordar GS, Larson G (2002) Cloning and sequencing of nineteen transcript isoforms of the human α2,3-sialyltransferase gene, ST3Gal III; its genomic organisation and expression in human tissues. Glycoconj J 19:197–210
Schnaar JL (2014) ST3 β-galactoside α-2,3-sialyltransferase 3 (ST3GAL3). In: Taniguchi N, Honke K, Fukuda M, Narimatsu H, Yamaguchi Y, Angata T (eds) Handbook of glycosyltransferases and related genes. Springer, Tokyo, pp 657–664
Okajima T, Fukumoto S, Miyazaki H, Ishida H, Kiso M, Furukawa K et al (1999) Molecular cloning of a novel α2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. J Biol Chem 274:11479–11486
Padro M, Cobler L, Garrido M, de Bolos C (2011) Down-regulation of FUT3 and FUT5 by shRNA alters Lewis antigens expression and reduces the adhesion capacities of gastric cancer cells. Biochim Biophys Acta 1810:1141–1149
Itai S, Arii S, Tobe R, Kitahara A, Kim YC, Yamabe H et al (1988) Significance of 2-3 and 2-6 sialylation of Lewis A antigen in pancreas cancer. Cancer 61:775–787
Itai S, Nishikata J, Yoneda T, Ohmori K, Tsunekawa S, Hiraiwa N et al (1991) Tissue distribution of sialyl 2-3 and 2-6 Lewis a antigens and the significance of serum 2-3/2-6 sialyl Lewis a antigen ratio for the differential diagnosis of malignant and benign disorders of the digestive tract. Cancer 67:1576–1587
Tsuchida A, Okajima T, Furukawa K, Ando T, Ishida H, Yoshida A et al (2003) Synthesis of disialyl Lewis a structure in colon cancer cell lines by a sialyltransferase ST6GalNAc VI responsible for the synthesis of α-series gangliosides. J Biol Chem 278:22787–22794
Miyazaki K, Ohmori K, Izawa M, Koike T, Kumamoto K, Furukawa K et al (2004) Loss of disialyl Lewisa, the ligand for lymphocyte inhibitory receptor Siglec-7, associated with increased sialyl Lewisa expression on human colon cancers. Cancer Res 64:4498–4505
Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529–1536
Taketo MM (2012) Roles of stromal microenvironment in colon cancer progression. J Biochem 151:477–481
Laubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA et al (2014) Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A 111:14211–14216
Bowden NA, Croft A, Scott RJ (2007) Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease. Hered Cancer Clin Pract 5:79–96
Young WW Jr, Mills SE, Lippert MC, Ahmed P, Lau SK (1988) Deletion of antigens of the Lewis a/b blood group family in human prostatic carcinoma. Am J Pathol 131:578–586
Potapenko IO, Haakensen VD, Luders T, Helland A, Bukholm I, Sorlie T et al (2010) Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol 4:98–118
Natunen S, Satomaa T, Pitkanen V, Salo H, Mikkola M, Natunen J et al (2011) The binding specificity of the marker antibodies Tra-1-60 and Tra-1-81 reveals a novel pluripotency-associated type 1 lactosamine epitope. Glycobiology 21:1125–1130
Tang C, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR et al (2011) An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 29:829–834
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kannagi, R., Cai, BH., Huang, HC., Chao, CC., Sakuma, K. (2018). Gangliosides and Tumors. In: Sonnino, S., Prinetti, A. (eds) Gangliosides. Methods in Molecular Biology, vol 1804. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8552-4_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8552-4_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8551-7
Online ISBN: 978-1-4939-8552-4
eBook Packages: Springer Protocols